Ionis Antisense Platform Safety Questioned After Thrombocytopenia Seen In Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK halts plans for Phase III study of antisense candidate in FAC due to FDA clinical hold for findings of reduced platelet counts in another Phase III trial; Ionis reveals similar findings in Phase III study of another antisense compound.